US biotech firms line up to list in Korea lured by strong valuations

Laboratory equipment. Photo: Pixabay

U.S. biotech firms are queuing up to list in South Korea, tempted by the promise of strong valuations amid a welcoming base of investors.

At least four such companies are seeking listings in the Asian country, according to NH Investment & Securities Co. and Eugene Investment & Securities Co. That’s a significant number given that there are currently only 20 overseas firms listed in South Korea, according to data compiled by Bloomberg.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter